Cargando…

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

Recent investigations of the tumor microenvironment have shown that many tumors are infiltrated by inflammatory and lymphocytic cells. Increasing evidence suggests that the number, type and location of these tumor-infiltrating lymphocytes in primary tumors has prognostic value, and this has led to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A, Capone, Mariaelena, Urba, Walter J, Bifulco, Carlo B, Botti, Gerardo, Lugli, Alessandro, Marincola, Francesco M, Ciliberto, Gennaro, Galon, Jérôme, Fox, Bernard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608225/
https://www.ncbi.nlm.nih.gov/pubmed/23452415
http://dx.doi.org/10.1186/1479-5876-11-54
_version_ 1782264205404012544
author Ascierto, Paolo A
Capone, Mariaelena
Urba, Walter J
Bifulco, Carlo B
Botti, Gerardo
Lugli, Alessandro
Marincola, Francesco M
Ciliberto, Gennaro
Galon, Jérôme
Fox, Bernard A
author_facet Ascierto, Paolo A
Capone, Mariaelena
Urba, Walter J
Bifulco, Carlo B
Botti, Gerardo
Lugli, Alessandro
Marincola, Francesco M
Ciliberto, Gennaro
Galon, Jérôme
Fox, Bernard A
author_sort Ascierto, Paolo A
collection PubMed
description Recent investigations of the tumor microenvironment have shown that many tumors are infiltrated by inflammatory and lymphocytic cells. Increasing evidence suggests that the number, type and location of these tumor-infiltrating lymphocytes in primary tumors has prognostic value, and this has led to the development of an ‘immunoscore. As well as providing useful prognostic information, the immunoscore concept also has the potential to help predict response to treatment, thereby improving decision- making with regard to choice of therapy. This predictive aspect of the tumor microenvironment forms the basis for the concept of immunoprofiling, which can be described as ‘using an individual’s immune system signature (or profile) to predict that patient’s response to therapy’ The immunoprofile of an individual can be genetically determined or tumor-induced (and therefore dynamic). Ipilimumab is the first in a series of immunomodulating antibodies and has been shown to be associated with improved overall survival in patients with advanced melanoma. Other immunotherapies in development include anti-programmed death 1 protein (nivolumab), anti-PD-ligand 1, anti-CD137 (urelumab), and anti-OX40. Biomarkers that can be used as predictive factors for these treatments have not yet been clinically validated. However, there is already evidence that the tumor microenvironment can have a predictive role, with clinical activity of ipilimumab related to high baseline expression of the immune-related genes FoxP3 and indoleamine 2,3-dioxygenase and an increase in tumor-infiltrating lymphocytes. These biomarkers could represent the first potential proposal for an immunoprofiling panel in patients for whom anti-CTLA-4 therapy is being considered, although prospective data are required. In conclusion, the evaluation of systemic and local immunological biomarkers could offer useful prognostic information and facilitate clinical decision making. The challenge will be to identify the individual immunoprofile of each patient and the consequent choice of optimal therapy or combination of therapies to be used.
format Online
Article
Text
id pubmed-3608225
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36082252013-03-27 The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment Ascierto, Paolo A Capone, Mariaelena Urba, Walter J Bifulco, Carlo B Botti, Gerardo Lugli, Alessandro Marincola, Francesco M Ciliberto, Gennaro Galon, Jérôme Fox, Bernard A J Transl Med Editorial Recent investigations of the tumor microenvironment have shown that many tumors are infiltrated by inflammatory and lymphocytic cells. Increasing evidence suggests that the number, type and location of these tumor-infiltrating lymphocytes in primary tumors has prognostic value, and this has led to the development of an ‘immunoscore. As well as providing useful prognostic information, the immunoscore concept also has the potential to help predict response to treatment, thereby improving decision- making with regard to choice of therapy. This predictive aspect of the tumor microenvironment forms the basis for the concept of immunoprofiling, which can be described as ‘using an individual’s immune system signature (or profile) to predict that patient’s response to therapy’ The immunoprofile of an individual can be genetically determined or tumor-induced (and therefore dynamic). Ipilimumab is the first in a series of immunomodulating antibodies and has been shown to be associated with improved overall survival in patients with advanced melanoma. Other immunotherapies in development include anti-programmed death 1 protein (nivolumab), anti-PD-ligand 1, anti-CD137 (urelumab), and anti-OX40. Biomarkers that can be used as predictive factors for these treatments have not yet been clinically validated. However, there is already evidence that the tumor microenvironment can have a predictive role, with clinical activity of ipilimumab related to high baseline expression of the immune-related genes FoxP3 and indoleamine 2,3-dioxygenase and an increase in tumor-infiltrating lymphocytes. These biomarkers could represent the first potential proposal for an immunoprofiling panel in patients for whom anti-CTLA-4 therapy is being considered, although prospective data are required. In conclusion, the evaluation of systemic and local immunological biomarkers could offer useful prognostic information and facilitate clinical decision making. The challenge will be to identify the individual immunoprofile of each patient and the consequent choice of optimal therapy or combination of therapies to be used. BioMed Central 2013-03-03 /pmc/articles/PMC3608225/ /pubmed/23452415 http://dx.doi.org/10.1186/1479-5876-11-54 Text en Copyright ©2013 Ascierto et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Ascierto, Paolo A
Capone, Mariaelena
Urba, Walter J
Bifulco, Carlo B
Botti, Gerardo
Lugli, Alessandro
Marincola, Francesco M
Ciliberto, Gennaro
Galon, Jérôme
Fox, Bernard A
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
title The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
title_full The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
title_fullStr The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
title_full_unstemmed The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
title_short The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
title_sort additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608225/
https://www.ncbi.nlm.nih.gov/pubmed/23452415
http://dx.doi.org/10.1186/1479-5876-11-54
work_keys_str_mv AT asciertopaoloa theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT caponemariaelena theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT urbawalterj theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT bifulcocarlob theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT bottigerardo theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT luglialessandro theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT marincolafrancescom theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT cilibertogennaro theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT galonjerome theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT foxbernarda theadditionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT asciertopaoloa additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT caponemariaelena additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT urbawalterj additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT bifulcocarlob additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT bottigerardo additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT luglialessandro additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT marincolafrancescom additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT cilibertogennaro additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT galonjerome additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment
AT foxbernarda additionalfacetofimmunoscoreimmunoprofilingasapossiblepredictivetoolforcancertreatment